dc.contributor.author |
Schellack, Natalie
|
|
dc.contributor.author |
Strydom, Morne A.
|
|
dc.contributor.author |
Pepper, Michael Sean
|
|
dc.contributor.author |
Herd, Candice Lee
|
|
dc.contributor.author |
Hendricks, Candice Laverne
|
|
dc.contributor.author |
Bronkhorst, Elmien
|
|
dc.contributor.author |
Meyer, Johanna C.
|
|
dc.contributor.author |
Padayachee, Neelaveni
|
|
dc.contributor.author |
Bangalee, Varsha
|
|
dc.contributor.author |
Truter, Ilse
|
|
dc.contributor.author |
Ellero, Andrea Antonio
|
|
dc.contributor.author |
Myaka, Thulisa
|
|
dc.contributor.author |
Naidoo, Elysha
|
|
dc.contributor.author |
Godman, Brian
|
|
dc.date.accessioned |
2023-04-24T09:33:00Z |
|
dc.date.available |
2023-04-24T09:33:00Z |
|
dc.date.issued |
2022-04 |
|
dc.description |
SUPPLEMENTARY MATERIAL : TABLE S1: Ivermectin Raw Utilisation Data; TABLE S2: Chloroquine Raw Utilisation Data; TABLE S3: Chloroquine Utilisation Data; TABLE S4: Colchicine Raw Utilisation Data; TABLE S5: Colchicine Time Series Utilisation Data; TABLE S6: Clinical trials within South Africa; TABLE S7: Global Chloroqine Clinical Trials; TABLE S8: Colchicine to Reduce Cardiac Injury in COVID-19 (COLHEART-19); TABLE S9: Global Ivermectin Clinical Trials; TABLE S10: Global Multi-drug Clinical Trials; TABLE S11: Clinical Trial Registration Dates; Table S12: Number of trials by status. |
en_US |
dc.description.abstract |
The capacity for social media to influence the utilization of re-purposed medicines to
manage COVID-19, despite limited availability of safety and efficacy data, is a cause for concern
within health care systems. This study sought to ascertain links between social media reports and
utilization for three re-purposed medicines: hydroxychloroquine (HCQ), ivermectin and colchicine.
A combined retrospective analysis of social media posts for these three re-purposed medicines was
undertaken, along with utilization and clinical trials data, in South Africa, between January 2020
and June 2021. In total, 77,257 posts were collected across key social media platforms, of which
6884 were relevant. Ivermectin had the highest number of posts (55%) followed by HCQ (44%). The
spike in ivermectin use was closely correlated to social media posts. Similarly, regarding chloroquine
(as HCQ is not available in South Africa), social media interest was enhanced by local politicians.
Sentiment analysis revealed that posts regarding the effectiveness of these repurposed medicines
were positive. This was different for colchicine, which contributed only a small number of mentions
(1%). Of concern is that the majority of reporters in social media (85%) were unidentifiable. This study
provides evidence of social media as a driver of re-purposed medicines. Healthcare professionals
have a key role in providing evidence-based advice especially with unidentifiable posts. |
en_US |
dc.description.department |
Immunology |
en_US |
dc.description.department |
Pharmacology |
en_US |
dc.description.librarian |
am2023 |
en_US |
dc.description.sponsorship |
Partly funded by the South African Medical Council (Extramural Unit, Stem Cell Research and Therapy) and the University of Pretoria (through the Institute for Cellular and Molecular Medicine), The Professor Bongani Mayosi Netcare Clinical Scholarship, The National Research Foundation and the University of Pretoria through the Institute for Cellular and Molecular Medicine. Other funding was provided by the different authors academic research funds. |
en_US |
dc.description.uri |
https://www.mdpi.com/journal/antibiotics |
en_US |
dc.identifier.citation |
Schellack, N.; Strydom, M.;
Pepper, M.S.; Herd, C.L.; Hendricks,
C.L.; Bronkhorst, E.; Meyer, J.C.;
Padayachee, N.; Bangalee, V.; Truter,
I.; et al. Social Media and
COVID-19—Perceptions and Public
Deceptions of Ivermectin, Colchicine
and Hydroxychloroquine: Lessons
for Future Pandemics. Antibiotics
2022, 11, 445. https://DOI.org/10.3390/antibiotics11040445. |
en_US |
dc.identifier.issn |
2079-6382 |
|
dc.identifier.other |
10.3390/antibiotics11040445 |
|
dc.identifier.uri |
http://hdl.handle.net/2263/90438 |
|
dc.language.iso |
en |
en_US |
dc.publisher |
MDPI |
en_US |
dc.rights |
© 2022 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license. |
en_US |
dc.subject |
Social media |
en_US |
dc.subject |
Re-purposed |
en_US |
dc.subject |
Medicines |
en_US |
dc.subject |
Hydroxychloroquine |
en_US |
dc.subject |
Ivermectin |
en_US |
dc.subject |
Colchicine |
en_US |
dc.subject |
Sentiment analysis |
en_US |
dc.subject |
Utilization |
en_US |
dc.subject |
Clinical trials |
en_US |
dc.subject |
South Africa (SA) |
en_US |
dc.subject |
COVID-19 pandemic |
en_US |
dc.subject |
Coronavirus disease 2019 (COVID-19) |
en_US |
dc.title |
Social media and COVID-19-perceptions and public deceptions of ivermectin, colchicine and hydroxychloroquine : lessons for future pandemics |
en_US |
dc.type |
Article |
en_US |